Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 11 October 2021 on Coronavirus: Drugs, whether his Department plans to make Ronapreve available for the treatment and prevention of covid-19 in immunocompromised patients; what the timeline is for Medicines and Healthcare products Regulatory Agency's consideration of ADZ7442; and whether his Department plans to seek prioritisation of that appraisal.

On 17 September, Ronapreve was made available to hospitalised patients through an interim NHS clinical policy. On 4 November 2021, the clinical policy was expanded. The clinical policy includes seronegative patients that are hospitalised for the management of acute COVID-19 infection and patients with hospital-onset COVID-19, if they are deemed to be at high risk of progression to severe COVID-19 or at risk of destabilising their condition or recovery from their procedure. This may include immunocompromised patients.

The Medicines and Healthcare products Regulatory Agency needs to ensure that products such as AZD7442 are of acceptable quality, safety and efficacy. This is an independent process and approval can only be determined when the full data has been provided by the manufacturer.